In:
Arteriosclerosis, Thrombosis, and Vascular Biology, Ovid Technologies (Wolters Kluwer Health), Vol. 26, No. 7 ( 2006-07), p. 1531-1537
Abstract:
Synthetic peptide inhibitor of NFAT selectively and potently inhibits NFAT activation and vSMC proliferation. NFAT and MEK-ERK pathways act in concert to trigger vSMC proliferation. NFAT is the key regulator essential for PDGF-BB-induced vSMC proliferation. VIVIT peptide may lead to more selective and less toxic approaches in antirestenosis therapy.
Type of Medium:
Online Resource
ISSN:
1079-5642
,
1524-4636
DOI:
10.1161/01.ATV.0000225286.30710.af
Language:
English
Publisher:
Ovid Technologies (Wolters Kluwer Health)
Publication Date:
2006
detail.hit.zdb_id:
1494427-3